Immunoprecipitation (IP) is a common research technique used to precipitate a specific protein (or protein complex) of interest out of a heterogeneous lysate. The concept of precipitating proteins out of solution is often called a "pull-down". There are a variety of methods to achieve immunoprecipitation, the most common of which uses antibodies bound to magnetic or agarose beads. This process can be used to isolate and concentrate a particular protein or complex from a sample containing many thousands of different proteins, and is often used to study protein-protein interactions through Co-IP experiments.
Novus offers a range of support options for IP when you buy a product to help you with your IP experiment including:
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-56116SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-101SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Purified | NBP3-25350SS | |||
| Purified | NBP3-25350 | |||
| BSA Free | NB100-110SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-77299SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-56113SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-13075SS | |||
| Azide and BSA Free | NBP2-80594 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-76769SS | |||
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Biotin | BBA9 | |||
| Fluorescein | BBA20 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | BBA20 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-2219SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | MAB25031-SP | |||
![Immunohistochemistry: Caspase-8 Antibody - (active/cleaved) [NB100-56116] - Autophagy-deficient mice showed increased activity of apoptosis and necroptosis. Reduced pancreatic Atg7 level increased the expression of Caspase-8 in 12-week-old Atg7deltapan mice. Caspase-8 quantitation and representative IF microphotographs of Atg7F/F (n=5) and Atg7deltapan (n=5) pancreatic tissue stained for DAPI (blue) and Caspase-8 (green) ( 1/1000, scale bar=50 um). Image collected and cropped by CiteAb from the following publication (//www.nature.com/doifinder/10.1038/cddis.2017.313), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Caspase-8-Antibody-active-cleaved-Immunohistochemistry-NB100-56116-img0009.jpg "Immunohistochemistry: Caspase-8 Antibody - (active/cleaved) [NB100-56116] - Autophagy-deficient mice showed increased activity of apoptosis and necroptosis. Reduced pancreatic Atg7 level increased the expression of Caspase-8 in 12-week-old Atg7deltapan mice. Caspase-8 quantitation and representative IF microphotographs of Atg7F/F (n=5) and Atg7deltapan (n=5) pancreatic tissue stained for DAPI (blue) and Caspase-8 (green) ( 1/1000, scale bar=50 um). Image collected and cropped by CiteAb from the following publication (//www.nature.com/doifinder/10.1038/cddis.2017.313), licensed under a CC-BY license.")
![Western Blot: Caspase-8 Antibody - (active/cleaved) [NB100-56116] - Analysis of active/cleaved Caspase 8 in NRK whole cell lysate using anti-active/cleaved Caspase 8 antibody. WB image submitted by a verified customer review.](http://images.novusbio.com/fullsize/Caspase-8-Antibody-active-cleaved-Western-Blot-NB100-56116-img0003.jpg)
![Immunohistochemistry-Paraffin: Caspase-8 Antibody - (active/cleaved) [NB100-56116] - Sections from a brain tumor tissue array stained for Caspase-8 expression using NB100-56116 at 1:2000. A. Anaplastic glioma (Grade III, left) and Gemistocytoma (Grade II, right) cores showing negative and positive staining for Caspase-8, respectively. B. Higher magnification of the Gemistocytoma tumor (from A).](http://images.novusbio.com/fullsize/Caspase-8-Antibody-active-cleaved-Immunohistochemistry-Paraffin-NB100-56116-img0004.jpg)
![Immunohistochemistry-Paraffin: Caspase-8 Antibody - (active/cleaved) [NB100-56116] - Sections from a brain tissue array stained for Caspase-8 expression using NB100-56116 at 1:2000. A. Normal brain stem (1) and cortex (2). B. Higher magnification of cortex (from A). C. Higher magnification of brain stem (from A). D. Normal cerebellum showing caspase-8 staining in the Purkinge cells.](http://images.novusbio.com/fullsize/Caspase-8-Antibody-active-cleaved-Immunohistochemistry-Paraffin-NB100-56116-img0005.jpg)
![Immunohistochemistry: Caspase-8 Antibody [NB100-56116] - Necroptosis marker p-MLKL can be detected in OA cartilage & after TNF/CHX stimulation.Exemplary images of impacted & differently stimulated cartilage explants after immunohistochemical staining of a cleaved CASP8, b RIPK3, & c p-MLKL. In addition, percentage of cleaved CASP8− (d) & p-MLKL− (e) positive cells was quantified (n = 3). Images were acquired using a 20× objective; the bars represent 200 µm Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31527653), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56116_rabbit-polyclonal-caspase-8-antibody-active-cleaved-imgenex-img-5703-310202415392576.jpg)
![Immunohistochemistry: Caspase-8 Antibody [NB100-56116] - Expression of necroptosis- & apoptosis-related markers is elevated in OA cartilage.Necroptosis- & apoptosis-related markers in highly degenerated cartilage tissue of OA patients (ICRS grade ≥ 3) were determined by a gene expression analysis of apoptosis & necroptosis markers as well as immunohistochemical analysis (IHC) of b cleaved CASP8, c RIPK3, & d p-MLKL. Macroscopically intact cartilage (ICRS grade ≤ 1) served as control. Bars in the IHC images represent 200 µm. Statistical analysis was performed by an unpaired multiple t test; error bars indicate median & range from min to max; n = 13. Significant differences between groups were depicted as: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31527653), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56116_rabbit-polyclonal-caspase-8-antibody-active-cleaved-imgenex-img-5703-310202415394549.jpg)
![Immunocytochemistry/ Immunofluorescence: Caspase-8 Antibody [NB100-56116] - Analysis of the cell type susceptible to apoptotic cell death in the hypothalamus of IRS2−/− mice. Immunoblots probed with antibodies against GFAP (A) & Tuj-1 (B) in the hypothalamus of wild-type (WT), non-diabetic IRS2-deficient (ND IRS2−/−) & diabetic IRS2-deficient (D IRS2−/−) mice. The average of three independent assays performed in duplicate is shown. Statistical significance by ANOVA: *P<0.05 vs WT mice. n=6/group. (C) Colocalization of TUNEL & GFAP in the hypothalamus of WT, ND IRS2−/− & D IRS2−/− mice. Arrows indicate astrocytes with apoptotic nuclei. (D) Colocalization of cleaved caspase-8 & GFAP, & of cleaved caspase-8 & NeuN, in the hypothalamus of WT, ND IRS2−/− & D IRS2−/− mice. Arrows indicate colocalization of GFAP & cleaved caspase-8. Scale bar: 50 µm; inset, 100 µm. Image collected & cropped by CiteAb from the following publication (//journals.biologists.com/dmm/article/doi/10.1242/dmm.023515/257174/Increased-oxidative-stress-and-apoptosis-in-the), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56116_rabbit-polyclonal-caspase-8-antibody-active-cleaved-imgenex-img-5703-31020241683918.jpg)
![Simple Western: APE Antibody [NB100-101] - Lane view shows a specific band for APE1 in 0.1 mg/ml of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/APE-Antibody-Simple-Western-NB100-101-img0011.jpg "Simple Western: APE Antibody [NB100-101] - Lane view shows a specific band for APE1 in 0.1 mg/ml of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.")
![Western Blot: APE Antibody [NB100-101] - Analysis of APE1 in cell lysates: 1. HeLa, 2. Ntera2, 3. A431, 4. HepG2, 5. MCF7, 6. NIH 3T3, 7. PC12, and 8. Cos 7.](http://images.novusbio.com/fullsize/APE-Antibody-Western-Blot-NB100-101-img0002.jpg)
![Immunohistochemistry: APE Antibody [NB100-101] - Immunohistochemical staining of APE-ref-1 in prostate cancer.](http://images.novusbio.com/fullsize/APE-Antibody-Immunohistochemistry-NB100-101-img0006.jpg)
![Western Blot: APE Antibody [NB100-101] - RKO cells were subjected to scrambled siRNA (Mock) or siRNA against TDP1 (TDP1KD) and cell lysates analyzed by immunoblotting (left). Control RKO (RKOSc siRNA) and RKO cells in which TDP1 levels were depleted (RKOTDP1 siRNA) were examined for their survival following exposure to the indicated doses of MMS, as described earlier in the text (right). Increasing the load of unrepaired methylated purines by exploiting the limited availability of TDP1 alone or in combination with canonical BER factors such as APE1 provides a new synthetic lethal setting to improve the clinical outcome of temozolomide-based cancer therapy. Image collected and cropped by CiteAb from the following publication (academic.oup.com/nar/article/42/5/3089/1051107), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/APE-Antibody-Western-Blot-NB100-101-img0012.jpg)
![Immunocytochemistry/Immunofluorescence: APE Antibody [NB100-101] - IF on HeLa cells. Image from verified customer review.](http://images.novusbio.com/fullsize/APE-Antibody-Immunocytochemistry-Immunofluorescence-NB100-101-img0009.jpg)
![Western Blot: APE Antibody [NB100-101] - SH-SY5Y (nuclear extract) tested at 1:1000 dilution. Image provided by verified customer review.](http://images.novusbio.com/fullsize/APE-Antibody-Western-Blot-NB100-101-img0008.jpg)
![Flow Cytometry: APE Antibody [NB100-101] - Spectral properties of Alexa Fluor(R) 488: an excitation maximum of 490 nm and an emission maximum of 525 nm. Use the Novus Spectra Viewer to identify the optimal laser(s) and filters for Alexa Fluor(R) 488 and to determine its compatibility with other fluorophores when designing a multicolor experiment. //www.novusbio.com/spectraviewer](http://images.novusbio.com/fullsize/APE-Antibody-Flow-Cytometry-NB100-101-img0013.jpg)
![Western Blot: APE Antibody [NB100-101] - Analysis of APE in human melanoma cell lysate using anti-APE antibody. Image from verified customer review.](http://images.novusbio.com/fullsize/APE-Antibody-Western-Blot-NB100-101-img0010.jpg)
![Immunocytochemistry/Immunofluorescence: APE Antibody [NB100-101] - Detection of APE1 (Green) in HepG2 cells using NB100-101. Nuclei (Blue) are counterstained with Hoechst 33258.](http://images.novusbio.com/fullsize/APE-Antibody-Immunocytochemistry-Immunofluorescence-NB100-101-img0007.jpg)
![Western Blot: APE Antibody - BSA Free [NB100-101] - Defective p53 activity leads to failure of the BER coordination system. (A) High-throughput microscopy analysis of TIG-1 cells transfected with plasmids expressing wild-type or mutant p53. Boxplots showing the distribution of APE1 staining intensity (in arbitrary units) in p53 low versus p53 overexpressing cells. Each p53 mutant is reported on top of the relevant plot. The dashed line highlights the median APE1 intensity in p53 low cells (N > 5000). NS: not statistically significant at P 8000). (D) Representative high-throughput immuno-fluorescence pictures showing TIG-1 cells stained for APE1 (right panel) & p53 (middle panel) after transfection with a p53 expressing plasmid. Cells that downregulating APE1 in response to p53 overexpression are marked by a contour line. Image collected & cropped by CiteAb from the following publication (//academic.oup.com/nar/article-lookup/doi/10.1093/nar/gkw015), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-101_rabbit-polyclonal-ape-antibody-310202415483627.jpg)
![Western Blot: APE Antibody - BSA Free [NB100-101] - Excessive AP-endonuclease activity in cells with p53 impairment leads to accumulation of genomic instability. (A) Representative western blotting analysis on WI38 (SV40) cells shows rescue of gamma H2AX staining upon co-depletion of XRCC1 & APE1. (B) Neutral Comet assay on WI38 (SV40) fibroblasts shows accumulation of DSBs upon XRCC1-depletion & rescue after co-depletion of XRCC1 & APE1. Results are expressed as mean ± SD of three independent experiments. (C) Representative western blotting analysis on WI38 (SV40) cells shows rescue of gamma H2AX staining after depletion of XRCC1 in presence of APE1 inhibitor III (APE1i III, 5 μM for 24 h), or AR03 (2.5 μM for 24 h). Actin was used as loading control in all western blotting experiments. Image collected & cropped by CiteAb from the following publication (//academic.oup.com/nar/article-lookup/doi/10.1093/nar/gkw015), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-101_rabbit-polyclonal-ape-antibody-31020241548519.jpg)
![Chromatin Immunoprecipitation: ARNT/HIF-1 beta Antibody [NB100-110] - ChIP analysis with ARNT/HIF-1 beta antibody [NB100-110]. Allele specific HIF-binding at the rs12814794 associated enhancer. B) Allele-specific qPCR for rs12814794 from DNA fragments isolated in HIF-ChIP experiments (HIF-1A and HIF-1B) or input DNA from primary renal tubular cells (PTC, n = 4 individuals). DNA from individuals homozygous for the AA or GG genotype were used as positive controls. C) Quantification of the two different alleles (A or G) at rs12814794 in the ChIP-seq reads from HIF-1A and HIF-1B immunoprecipitations (PTC #1 Fig 3). Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pgen.1006872) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/ARNT-HIF-1-beta-Antibody-Chromatin-Immunoprecipitation-NB100-110-img0007.jpg "Chromatin Immunoprecipitation: ARNT/HIF-1 beta Antibody [NB100-110] - ChIP analysis with ARNT/HIF-1 beta antibody [NB100-110]. Allele specific HIF-binding at the rs12814794 associated enhancer. B) Allele-specific qPCR for rs12814794 from DNA fragments isolated in HIF-ChIP experiments (HIF-1A and HIF-1B) or input DNA from primary renal tubular cells (PTC, n = 4 individuals). DNA from individuals homozygous for the AA or GG genotype were used as positive controls. C) Quantification of the two different alleles (A or G) at rs12814794 in the ChIP-seq reads from HIF-1A and HIF-1B immunoprecipitations (PTC #1 Fig 3). Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pgen.1006872) licensed under a CC-BY license.")
![Western Blot: ARNT/HIF-1 beta Antibody [NB100-110] - Analysis of HIF-1 beta using ARNT/HIF-1 beta antibody [NB100-110] in MCF7 whole cell lysate. Theoretical molecular weight is 86.6 kDa. Observed molecular weight ~95 kDa.](http://images.novusbio.com/fullsize/ARNT-HIF-1-beta-Antibody-Western-Blot-NB100-110-img0001.jpg)
![Immunohistochemistry: ARNT/HIF-1 beta Antibody [NB100-110] - Immunohistochemical staining of human skin epidermis with ARNT/HIF-1 beta antibody [NB100-110].](http://images.novusbio.com/fullsize/ARNT-HIF-1-beta-Antibody-Immunohistochemistry-NB100-110-img0004.jpg)
![Chromatin Immunoprecipitation: ARNT/HIF-1 beta Antibody [NB100-110] - ChIP analysis with ARNT/HIF-1 beta antibody [NB100-110]. MDA-MB-231 cells were exposed to 20% or 1% O2 for 16 hours, and chromatin immunoprecipitation (ChIP) was performed with the indicated antibody (Ab). Primers flanking the HIF binding site were used for qPCR. ChIP image submitted by a verified customer review.](http://images.novusbio.com/fullsize/ARNT-HIF-1-beta-Antibody-Chromatin-Immunoprecipitation-NB100-110-img0009.jpg)
![Chromatin Immunoprecipitation (ChIP): ARNT/HIF-1 beta Antibody [NB100-110] - ChIP analysis using ARNT/HIF-1 beta antibody [NB100-110]. MCF7 were exposed to 20% or 1% O2 for 16h, and ChIP assays were performed using IgG or antibodies against HIF-1a, HIF-2a, HIF-1b. ChIP image submitted by a verified customer review.](http://images.novusbio.com/fullsize/ARNT-HIF-1-beta-Antibody-Chromatin-Immunoprecipitation-ChIP-NB100-110-img0006.jpg)
![Chromatin Immunoprecipitation: ARNT/HIF-1 beta Antibody [NB100-110] - ChIP analysis with ARNT/HIF-1 beta antibody [NB100-110]. A scatter plot showing HIF-1B ChIP-seq signal at the same set of binding sites exhibiting a comparable increase in HIF-1B binding in cells expressing transfected HIF-2A. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0134645) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/ARNT-HIF-1-beta-Antibody-Chromatin-Immunoprecipitation-NB100-110-img0008.jpg)
![Simple Western: ARNT/HIF-1 beta Antibody [NB100-110] - Simple Western analysis using ARNT/HIF-1 beta antibody [NB100-110]. Lane view shows a specific band for HIF-1 beta in 0.5 mg/ml of Hypoxic HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system. Theoretical molecular weight is 86.6 kDa. Observed molecular weight ~106 kDa.](http://images.novusbio.com/fullsize/ARNT-HIF-1-beta-Antibody-Simple-Western-NB100-110-img0005.jpg)
![Western Blot: RIPK3/RIP3 Antibody [NBP1-77299] - Analysis of RIP3 in HeLa cell lysate with RIPK3/RIP3 antibody [NBP1-77299] at (A) 1 and (B) 2 ug/mL. Observed molecular weight ~60 kDa. Theoretical molecular weight 53 kDa.](http://images.novusbio.com/fullsize/RIPK3-RIP3-Antibody-Western-Blot-NBP1-77299-img0014.jpg "Western Blot: RIPK3/RIP3 Antibody [NBP1-77299] - Analysis of RIP3 in HeLa cell lysate with RIPK3/RIP3 antibody [NBP1-77299] at (A) 1 and (B) 2 ug/mL. Observed molecular weight ~60 kDa. Theoretical molecular weight 53 kDa.")
![Western Blot: RIPK3/RIP3 Antibody [NBP1-77299] - Mouse Cell lines. 15 ug of lysates per lane. Antibodies: [NBP1-77299], (0.5 ug/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. Observed molecular weight ~50 kDa. Theoretical molecular weight 53 kDa.](http://images.novusbio.com/fullsize/RIPK3-RIP3-Antibody-Western-Blot-NBP1-77299-img0022.jpg)
![Western Blot: RIPK3/RIP3 Antibody [NBP1-77299] - Analysis using RIPK3/RIP3 antibody [NBP1-77299]. L929 cell line (mouse). 20 ug whole cell lysate. Primary antibody: 1:2000. Secondary antibody: 1:20000. Western blot image submitted by a verified customer review. Observed molecular weight ~57 kDa. Theoretical molecular weight 53 kDa.](http://images.novusbio.com/fullsize/RIPK3-RIP3-Antibody-Western-Blot-NBP1-77299-img0024.jpg)
![Western Blot: RIPK3/RIP3 Antibody [NBP1-77299] - C2C12 Cells. 15 ug of lysates per lane. Antibodies: RIPK3/RIP3 antibody [NBP1-77299], 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. Lane 1: NBP1-77299, 0.1 ug/mL in the presence of peptide blocking. Lane 2: NBP1-77299, 0.1 ug/mL Lane 3: NBP1-77299, 0.2 ug/mL Lane 4: NBP1-77299, 0.5 ug/mL. Observed molecular weight ~55 kDa. Theoretical molecular weight 53 kDa.](http://images.novusbio.com/fullsize/RIPK3-RIP3-Antibody-Western-Blot-NBP1-77299-img0021.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: RIPK3/RIP3 Antibody [NBP1-77299] - Bone-marrow-derived macrophages exhibit significant reduction in RIPK3/RIP3 levels in RIPK3/RIP3deltaGlobal, RIPK3/RIP3deltaMphi-Cre and RIPK3/RIP3deltaEC-Cre mice. Protein lysates were immunoblotted to identify CD11b, RIPK3/RIP3 and beta-actin (loading control). Image collected and cropped by CiteAb from the following publication (www.dmm.biologists.org/lookup/doi/10.1242/dmm.041962) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/RIPK3-RIP3-Antibody-Knockout-Validated-NBP1-77299-img0025.jpg)
![<b>Genetic Strategies Validation. </b>Knockdown Validated: RIPK3/RIP3 Antibody [NBP1-77299] - RIPK3/RIP3-deficiency impacts MCP-1 and IL-1beta expression in BMDMs and MCP-1 and E-Selectin/CD62E expression in cultured endothelial cells. Protein lysates were immunoblotted for RIPK3/RIP3 and the loading control, GAPDH (n=4 independent experiments). Image collected and cropped by CiteAb from the following publication (www.dmm.biologists.org/content/13/1/dmm041962) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/RIPK3-RIP3-Antibody-Knockdown-Validated-NBP1-77299-img0026.jpg)
![Western Blot: RIPK3/RIP3 Antibody - BSA Free [NBP1-77299] - Bone-marrow-derived macrophages exhibit significant reduction in RIPK3 levels in Ripk3 delta Global, Ripk3 delta MΦ-Cre & Ripk3 delta EC-Cre mice. (A,B) BMDMs were isolated, differentiated on chamber slides for 7 days, immunostained for macrophage markers CD68 (red; A) & CD11b (pink; B), & co-stained for nuclei (Hoechst; blue). All cells from seven separate BMDM isolations were positive for these markers (n=7). (C) A phagocytosis assay was performed on BMDMs with fluorescent polystyrene beads. Phagocytic cells display TRITC+/Hoechst+ signal, & 85% of cells from two separate BMDM isolations were double positive (n=2). (D-F) Protein or RNA was collected from control, Ripk3 delta Global, Ripk3 delta MΦ-Cre & Ripk3 delta EC-Cre BMDMs. RNA was converted to cDNA & analyzed by qPCR for Ripk3 levels (D). Protein lysates were immunoblotted to identify CD11b, RIPK3 & beta -actin (loading control) (E) & quantified (F). (G) RNA from control & Ripk3 delta Global BMDMs was converted to cDNA & analyzed by qPCR for Ripk3-Exon 10 levels. For panels D,F,G, each dot represents a BMDM isolation from an individual animal. Statistics for panels D & F were calculated using one-way ANOVA with Dunnett's multiple comparisons test. Overall ANOVA P-values (prior to the post hoc tests) are 0.0002 (D) & <0.0001 (F). Statistics for panel G were calculated using an unpaired t-test with Welch's correction. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. Data are mean±s.d. Scale bars: 25 µm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31953345), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-77299_rabbit-polyclonal-ripk3-rip3-antibody-310202416171485.jpg)
![Western Blot: RIPK3/RIP3 Antibody - BSA Free [NBP1-77299] - p-MLKL levels are nearly undetectable in advanced plaques. (A-C) After 3 months on a Western diet, protein was collected from control (n=7), Ripk3 delta MΦ-Cre (n=5), Ripk3 delta EC-Cre (n=3) & Ripk3 delta SMC-Cre (n=3) aortas. Protein lysates were immunoblotted to identify p-MLKL (Abcam; #ab196436), MLKL & beta -actin (loading control) (A) & quantified (B,C). A faint positive p-MLKL signal can be seen in the representative blot in the control arch region; however, we could only detect p-MLKL in two out of the 18 aortas analyzed (B). Note that the same transfer membrane used for detecting CD11b (in Fig. 4S) was reprobed for p-MLKL & MLKL in A; the beta -actin control blots are therefore the same in both figures. (D,E) Protein lysates were immunoblotted to identify RIPK3 & GAPDH (loading control) (D) & quantified (E). For panels B,C,E, each dot represents an individual animal. Statistics were calculated using two-way ANOVA. Overall ANOVA P-values are 0.76 (B), 0.07 (C) & 0.46 (E). Data are mean±s.d. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31953345), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-77299_rabbit-polyclonal-ripk3-rip3-antibody-31020241616072.jpg)
![Immunocytochemistry/ Immunofluorescence: RIPK3/RIP3 Antibody - BSA Free [NBP1-77299] - Validation of RIPK3/RIP3 in Rat Kidney Tissue. Immunofluorescent analysis of 4% paraformaldehyde-fixed Rat Kidney tissue labeling RIPK3/RIP3 with at 20 ug/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (red).](http://images.novusbio.com/fullsize/nbp1-77299_rabbit-polyclonal-ripk3-rip3-antibody-2711202419562182.jpg)
![Immunohistochemistry: RIPK3/RIP3 Antibody - BSA Free [NBP1-77299] - Validation of RIPK3/RIP3 in Mouse Kidney Tissue. Immunohistochemical analysis of paraffin-embedded mouse kidney tissue using anti-RIPK3/RIP3 antibody at 2.5 ug/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.](http://images.novusbio.com/fullsize/nbp1-77299_rabbit-polyclonal-ripk3-rip3-antibody-2711202419333448.gif)
![Immunohistochemistry: RIPK3/RIP3 Antibody - BSA Free [NBP1-77299] - Validation of RIPK3/RIP3 in Rat Kidney Tissue.Immunohistochemical analysis of paraffin-embedded rat kidney tissue using anti-RIPK3/RIP3 antibody at 5 ug/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.](http://images.novusbio.com/fullsize/nbp1-77299_rabbit-polyclonal-ripk3-rip3-antibody-271120242074698.jpg)
![Western Blot: RIPK3/RIP3 Antibody - BSA Free [NBP1-77299] - Validation in Human Cell Lines. Loading: 15 ug of lysates per lane.Antibodies: RIPK3/RIP3 , (0.5 ug/mL), 1h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.](http://images.novusbio.com/fullsize/nbp1-77299_rabbit-polyclonal-ripk3-rip3-antibody-2711202420243399.gif)
![Immunohistochemistry: Caspase-3 Antibody - (active/cleaved) [NB100-56113] - Immunohistochemistry analysis of sectioned tumor tissues from the MDA-MB-231 study. Each section was subjected to the specified antibody followed by a biotinylated secondary antibody. Detection was done using a DAB Peroxidase HRP Substrate Kit (brown) followed by Hematoxylin counterstaining (purple). Images were obtained using inverted bright field microscopy. Sectioning results are representative of three individual tumors. Scale bar is 50 microns. Statistical analysis using One-Way ANOVA. *p<0.05 vs tumor volume of the control. Image collected and cropped by CiteAb from the following publication (nature.com/articles/s41598-017-01230-4), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Caspase-3-Antibody-active-cleaved-Immunohistochemistry-NB100-56113-img0005.jpg "<b>Biological Strategies Validation. </b>Immunohistochemistry: Caspase-3 Antibody - (active/cleaved) [NB100-56113] - Immunohistochemistry analysis of sectioned tumor tissues from the MDA-MB-231 study. Each section was subjected to the specified antibody followed by a biotinylated secondary antibody. Detection was done using a DAB Peroxidase HRP Substrate Kit (brown) followed by Hematoxylin counterstaining (purple). Images were obtained using inverted bright field microscopy. Sectioning results are representative of three individual tumors. Scale bar is 50 microns. Statistical analysis using One-Way ANOVA. *p<0.05 vs tumor volume of the control. Image collected and cropped by CiteAb from the following publication (nature.com/articles/s41598-017-01230-4), licensed under a CC-BY license.")
![<b>Biological Strategies Validation. </b>Western Blot: Caspase-3 Antibody - (active/cleaved) [NB100-56113] - The protein expression levels of Bcl-2, Bax and cleaved caspase-3 were detected in the different groups using Western blotting and were normalized to the housekeeping gene GAPDH. Image collected and cropped by CiteAb from the following publication (onlinelibrary.wiley.com/doi/abs/10.1111/jcmm.14135), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Caspase-3-Antibody-active-cleaved-Western-Blot-NB100-56113-img0006.jpg)
![Western Blot: Caspase-3 Antibody - (active/cleaved) [NB100-56113] - Cell apoptosis was detected by flow cytometric analysis, and the percentage of apoptotic cells transfected with miR-200c inhibitor or NC inhibitor and treated with AngII or PBS for 48 h was determined. Image collected and cropped by CiteAb from the following publication (onlinelibrary.wiley.com/doi/abs/10.1111/jcmm.14135), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Caspase-3-Antibody-active-cleaved-Western-Blot-NB100-56113-img0007.jpg)
![Immunohistochemistry-Paraffin: Caspase-3 Antibody - (active/cleaved) [NB100-56113] - Dog ischemic brain stained for Active/Cleaved Caspase-3 expression using Caspase-3 Antibody - (active/cleaved)( NB100-56113) at 1:2000. Staining is seen in the nuclei of dying neurons (black arrow) but not in the morphologically normal nuclei (open arrows). Caspase-3 expression in the nucleus is considered to be a marker of active/caspase-3 expression and apoptosis. Hematoxylin-eosin counterstain.](http://images.novusbio.com/fullsize/Caspase-3-Antibody-active-cleaved-Immunohistochemistry-Paraffin-NB100-56113-img0003.jpg)
![Immunohistochemistry-Paraffin: Caspase-3 Antibody - (active/cleaved) [NB100-56113] - Irradiated mouse spleen stained for Active/Cleaved Caspase-3 expression using Caspase-3 Antibody - (active/cleaved) (NB100-56113) at 1:2000. Staining is seen in the nuclei of a subset of the cell population. Caspase-3 expression in the nucleus is considered to be a marker of active/caspase-3 expression and apoptosis. Hematoxylin-eosin counterstain.](http://images.novusbio.com/fullsize/Caspase-3-Antibody-active-cleaved-Immunohistochemistry-Paraffin-NB100-56113-img0004.jpg)
![Immunohistochemistry: Caspase-3 Antibody - (active/cleaved) [NB100-56113] - Pathology in DOX treated acute & recovery phase mice. Regions of myofiber loss & frank replacement fibrosis were noted, most commonly in atria (A, acute phase), & rarely in ventricles (D, recovery phase). These areas were accompanied by macrophage infiltration (B, E) & myofibroblast proliferation (C) consistent with fibroplasia. Rare myofibers were matrix metalloproteinase 2 (F, recovery phase animal) or caspase-3 positive (G, acute phase animal). Reticulin staining (A, D); Immunohistochemistry: Iba 1(B, E; macrophages), alpha SMA (C), MMP-2 (F) & cleaved caspase -3 (G) Bar = 100µm (A-C); 50µm (D-F); 20µm (G). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31263061), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56113_rabbit-polyclonal-caspase-3-antibody-active-cleaved-31020241530428.jpg)
![Western Blot: Caspase-3 Antibody - (active/cleaved) [NB100-56113] - Antidepressants-mediated effect on cellular protein content. HT-22 cells were treated with antidepressants for 48 & 96 h & densitometry analysis of NF-kappa B (b), p16 (c), p21 (d), p27 (e), p53 (f), TRF1 (g), TRF2 (h), calnexin (i), NuMa (j), cleaved caspase 3 (k), Bcl-2 (l) was evaluated. Representative Western Blots are presented (a). Bars indicate SD, n = 3, ***/^^^p < 0.001, **/^^p < 0.01, */^p < 0.05, no indication—no statistical significance (one-way ANOVA & Dunnett’s a posteriori test) Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31278507), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56113_rabbit-polyclonal-caspase-3-antibody-active-cleaved-310202415175224.jpg)
![Immunocytochemistry/ Immunofluorescence: Caspase-3 Antibody - (active/cleaved) [NB100-56113] - Morphological changes & expression of key apoptosis-related molecules in 4T1 cells after DE-EDCP treatment(A) Morphological changes of 4T1 cells exposed to various concentrations of DE-EDCP for 24h. (B) Immunofluorescence staining for Bcl-2 (green), Bax (green) & cleaved caspase-3 (green) together with DNA staining with DAPI (blue) in 4T1 cells incubated with DE-EDCP or cisplatin (31.25 μM) for 24h, as well as in untreated cells (magnification at x200). (C) mRNA expression of Bcl-2, Bax & caspase-3 quantified by RT-PCR in 4T1 cells after DE-EDCP 24h treatment. DE-EDCP treatment markedly increased the expression of Bax & caspase-3 mRNA & decreased the expression of Bcl-2 mRNA in 4T1 cells. beta -actin mRNA was used as an internal control. Data points are represented by the expression ratio & mean±SD fold of control in 4T1 cells. (* Bcl-2-: DE-EDCP vs. untreated p=0.03; DE-EDCP vs. cisplatin p=0.006; cislatin vs. untreated p=0.001; Bax-: DE-EDCP vs. untreated p=0.011; cislatin vs. untreated p=0.009; caspase-3-: DE-EDCP vs. untreated p=0.015; DE-EDCP vs. cisplatin p=0.021) Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.25610), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56113_rabbit-polyclonal-caspase-3-antibody-active-cleaved-31020241682116.jpg)
![Immunocytochemistry/ Immunofluorescence: beta Amyloid Antibody (MOAB-2) - BSA Free [NBP2-13075] - No difference in A beta plaque load between propofol (n = 8) & vehicle (n = 6) treated APP/PS1 mice. a An example image of A beta plaque immunoreactivity in the cortex of an APP/PS1 mouse following repeated propofol exposure. b A representative image of A beta plaque immunolabeling the cortex of an APP/PS1 mouse following treatment with vehicle. c Bar graph showing the percentage of the cortex occupied by A beta plaques in propofol & vehicle treated APP/PS1 mice. d Bar graph showing the average size (μm2) of A beta plaques in the cortex of APP/PS1 in the propofol & vehicle treatment groups. e Bar graph showing the average density of A beta plaques (/μm2) in the cortex of propofol & vehicle exposed APP/PS1 mice. All data is shown as mean ± SEM. Scale bar = 500 μm Image collected & cropped by CiteAb from the following publication (//bmcanesthesiol.biomedcentral.com/articles/10.1186/s12871-018-0509-5), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-13075_mouse-monoclonal-beta-amyloid-antibody-moab-2-310202416114798.jpg)
![Western Blot: PD-L1 Antibody [NBP1-76769] - Validation with PD-L1 siRNA Knockdown. HeLa cells were transfected with control siRNAs (lane 1) or PD-L1 siRNAs (lane 2). Loading: 10 ug of HeLa whole cell lysates per lane. Antibodies: NBP1-76769 (2 ug/mL) and GAPDH (0.02 ug/mL), 1 h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Knockdown-Validated-NBP1-76769-img0024.jpg "<b>Genetic Strategies Validation. </b>Western Blot: PD-L1 Antibody [NBP1-76769] - Validation with PD-L1 siRNA Knockdown. HeLa cells were transfected with control siRNAs (lane 1) or PD-L1 siRNAs (lane 2). Loading: 10 ug of HeLa whole cell lysates per lane. Antibodies: NBP1-76769 (2 ug/mL) and GAPDH (0.02 ug/mL), 1 h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.")
![<b>Independent Antibodies Validation and Genetic Strategies Validation.</b>Western Blot: PD-L1 Antibody [NBP1-76769] - Independent Antibody Validation (IAV) via Protein Expression ProfileLoading: 15 ug of lysates per lane.Antibodies: NBP1-76769 (2 ug/mL), PD-L1 (2 ug/mL), and beta-actin (1 ug/mL), 1 h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit and or anti-mouse IgG HRP conjugate at 1:10000 and 1:5000 dilution, respectively.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Western-Blot-NBP1-76769-img0023.jpg)
![Immunohistochemistry-Paraffin: PD-L1 Antibody [NBP1-76769] - CD274 (PD-L1) expression in the HNSCC patients from the TCGA database , HNSCC tissue samples and the HNSCC cells. Immunostaining of PD-L1 obtained from HNSCC tumor cells, immune cells and tumor margin tissues in HNSCC tissue samples (magnification A-200, scale bars 50AI1/4m) : low tumor staining; moderate tumor staining; high tumor staining have been observed. Image collected and cropped by Citeab from the following publication (Lactoferricin B reverses cisplatin resistance in head and neck squamous cell carcinoma cells through targeting PD-L1. Cancer Med (2018)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Immunohistochemistry-Paraffin-Negative-NBP1-76769-img0025.jpg)
![Western Blot: PD-L1 Antibody [NBP1-76769] - PD-L1 expression was evaluated in gastric cancer cells. Levels of PD-L1 protein were assessed in normal human gastric epithelial cells and 8 gastric cancer cell lines by Western blots. Image collected and cropped by Citeab from the following publication (Autophagy inhibition enhances PD-L1 expression in gastric cancer. J Exp Clin Cancer Res (2019)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Western-Blot-NBP1-76769-img0026.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: PD-L1 Antibody [NBP1-76769] - Upregulated expression of PD-L1 in cisplatin-resistant cells through IL-6/STAT3. Image collected and cropped by Citeab from the following publication (Lactoferricin B reverses cisplatin resistance in head and neck squamous cell carcinoma cells through targeting PD-L1. Cancer Med (2018)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Western-Blot-NBP1-76769-img0027.jpg)
![Western Blot: PD-L1 Antibody [NBP1-76769] - CD274 (PD-L1) expression in the HNSCC patients from the TCGA databas HNSCC cells. CD274 expression with survival and its relation with therapy in the HNSCC patients from the TCGA database. Expression of CD274 gene and PD-L1 protein in the established cisplatin-resistant HNSCC cells and cisplatin sensitive cells by qRT-PCR and WB (F, H): CD274 (PD-L1) expressed in cisplatin resistant cell. Image collected and cropped by Citeab from the following publication (Lactoferricin B reverses cisplatin resistance in head and neck squamous cell carcinoma cells through targeting PD-L1. Cancer Med (2018)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Western-Blot-NBP1-76769-img0028.jpg)
![Immunocytochemistry/Immunofluorescence: PD-L1 Antibody [NBP1-76769] - U-251 MG cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti- NBP1-76769 at 1 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-76769-img0029.jpg)
![Flow Cytometry: PD-L1 Antibody [NBP1-76769] - An intracellular stain was performed on U-251 MG cells with PD-L1 Antibody NBP1-76769 (blue) and a matched isotype control NBP2-24891 (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (SA5-10033, Thermo Fisher).](http://images.novusbio.com/fullsize/PD-L1-Antibody-Flow-Cytometry-NBP1-76769-img0030.jpg)
![Western Blot: PD-L1 Antibody [NBP1-76769] - Expression of CD274 in Human melanoma SK-MEL-28 cell line upon treatment with 200 mM ethanol. Dilution: 1:1,000 in PBS with 5% BSA. Secondary Ab: anti-Rabbit IgG 1:5,000. Western blot image submitted by a verified customer review.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Western-Blot-NBP1-76769-img0019.jpg)
![Immunohistochemistry-Paraffin: PD-L1 Antibody [NBP1-76769] - B7-H1/PD-L1/CD274 Antibody [NBP1-76769] - Human tonsil tissue with PD-L1 antibody at 5 ug/mL.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Immunohistochemistry-Paraffin-NBP1-76769-img0017.jpg)
![Immunohistochemistry-Paraffin: PD-L1 Antibody [NBP1-76769] - Staining of human heart tissue with antibody at 2.5 ug/mL.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Immunohistochemistry-Paraffin-NBP1-76769-img0010.jpg)
![Immunohistochemistry-Paraffin: PD-L1 Antibody [NBP1-76769] - PD-L1/B7-H1 Antibody [NBP1-76769] - PD-L1 in rat heart tissue with at 5 ug/mL.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Immunohistochemistry-Paraffin-NBP1-76769-img0020.jpg)
![Flow Cytometry: PD-L1 Antibody [NBP1-76769] - B7-H1/PD-L1/CD274 Antibody [NBP1-76769] - Analysis of A-20 cells using B7-H1/PD-L1/CD274 antibody at 0.5 ug/mL. Green: Isotype control. Red : B7-H1/PD-L1/CD274 antibody.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Flow-Cytometry-NBP1-76769-img0018.jpg)
![Immunofluorescence: PD-L1 Antibody [NBP1-76769] - Human Heart cells with PD-L1 antibody at 20 ug/mL.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Immunofluorescence-NBP1-76769-img0009.jpg)
![Dual RNAscope ISH-IHC: PD-L1 Antibody [NBP1-76769] - PDCD1 mRNA (red) and PD-L1 protein (green) were detected in formalin-fixed paraffin-embedded tissue sections of human lung cancer. ACD's Integrated Co-Detection Workflow was performed using ACD RNAScope Probe Hs-PDCD1 and PD-L1 antibody at 1:100 dilution. Tissue was stained on Leica Bond RX using RNAscope (TM) 2.5 LS Reagent Kit-RED, BOND Polymer Refine Detection (DAB) and Hematoxylin, BOND Polymer Refine Red Detection and Hematoxylin and RNAscope (TM) 2.5 LS Green Accessory Pack. Tissue was counterstained with 50% hematoxylin (blue).](http://images.novusbio.com/fullsize/PD-L1-Antibody-Dual-RNAscope-ISH-IHC-NBP1-76769-img0031.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - ROS mediated PD-L1 upregulation in FFA-treated LO2 cells. (a) Intracellular ROS in LO2 cells before & after FFA treatment measured by DCFH-DA. (b–d) Expression levels of NOX2 & NOX4 measured using qRT-PCR & western blot. (e) JC-1 probes were used to detect mitochondrial membrane potential. (f–j) Intracellular ROS in LO2 cells pretreated with siRNA against NOX4, MitoTEMPO (10 μM), or NAC (5 mM) followed by FFA treatment, measured by DCFH-DA, PD-L1 expression determined by western blot. ∗∗P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35615575), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202415382415.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - Inhibition of NF-kappa B or STAT3 downregulated PD-L1 expression in adi-CM model. a PD-L1 protein levels in HepG2 cells treated with different concentration of NF-kappa B inhibitor, withaferin A (WA). b PD-L1 protein levels in HepG2 cells treated with different concentration of STAT3 inhibitor, BP-1-102. c PD-L1 protein levels in B16-F1 cells incubated with WA. Data are expressed as mean ± SEM, n = 6, **P < 0.01, ***P < 0.001 Vs adi-CM group. ##P < 0.01 & ###P < 0.001 Vs DMSO group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32477009), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-31020241534538.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - PD-L1 expression levels in liver samples & FFA-treated LO2 cells. (a–d) PD-L1 expression & CD8+ T cells in the liver tissues determined by immunohistochemistry. (e) Intracellular lipid accumulation after FFA treatment (0.8 mM) for 24 hour measured by Oil Red staining. (f–i) Expression levels of PD-L1 detected by qRT-PCR, western blot, & immunofluorescence. ∗∗P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35615575), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202415175299.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - Inhibition of NF-kappa B or STAT3 downregulated PD-L1 expression in adi-CM model. a PD-L1 protein levels in HepG2 cells treated with different concentration of NF-kappa B inhibitor, withaferin A (WA). b PD-L1 protein levels in HepG2 cells treated with different concentration of STAT3 inhibitor, BP-1-102. c PD-L1 protein levels in B16-F1 cells incubated with WA. Data are expressed as mean ± SEM, n = 6, **P < 0.01, ***P < 0.001 Vs adi-CM group. ##P < 0.01 & ###P < 0.001 Vs DMSO group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32477009), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202415291978.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - Inhibition of NF-kappa B or STAT3 downregulated PD-L1 expression in adi-CM model. a PD-L1 protein levels in HepG2 cells treated with different concentration of NF-kappa B inhibitor, withaferin A (WA). b PD-L1 protein levels in HepG2 cells treated with different concentration of STAT3 inhibitor, BP-1-102. c PD-L1 protein levels in B16-F1 cells incubated with WA. Data are expressed as mean ± SEM, n = 6, **P < 0.01, ***P < 0.001 Vs adi-CM group. ##P < 0.01 & ###P < 0.001 Vs DMSO group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32477009), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202415175210.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - ROS/ZNF24/PD-L1 pathway activation in NAFLD models. (a) Intracellular ROS in hepatocytes in NAFLD significantly increased. (b) JC-1 probes were used to detect mitochondrial membrane potential. (c & d) NOX4 & ZNF24 expressions were determined by immunohistochemistry. (e & f) ROS/ZNF24/PD-L1 pathway activation examined by western blot. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35615575), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202415284517.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - PD-L1 limits liver injury in NAFLD models. (a & b) Western blot determined the effect of siRNA against PD-L1. (c) After PD-L1 knockdown, mRNA expression levels of markers of T cell activation measured by qRT-PCR. (d & e) Hepatocyte injury was evaluated by the Tunel assay & ALT/AST measurement. (f) Graph illustrating that both ROS/ZNF24 pathway activation & UBE2I-mediated ZNF24 sumoylation suppression induced by FFA promoted PD-L1 expression. ∗P < 0.05, ∗∗P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35615575), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-31020241529331.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - PD-L1 knockdown aggravated the damage of CD8 + T cells to FFA-treated LO2 cells. (a & b) Western blot determined the effect of siRNA against PD-L1. Coculturing of FFA-treated LO2 cells & CD8 + T cells in vitro. (c) mRNA expression levels of markers of T cell activation measured by qRT-PCR, (d) LO2 cell injury was evaluated by LDH assay, (e) AST or ALT in the supernatants measured by commercial assay kits. # represents that CD8 + T cells were incubated separately with LO2 cells, but supernatants were put together. ∗P < 0.05, ∗∗P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35615575), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202415304228.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - Upregulated expression of PD‐L1 in cisplatin‐resistant cells through IL‐6/STAT3. The cisplatin resistant CAL27cis & Detroit‐562cis cells had increased IL‐6 mRNA & IL‐6 protein production compared to parental cells by qRT‐PCR & ELISA (A, B). CAL27cis & Detroit‐562cis were cultured with IL‐6 (10 ng/mL, human recombinant IL‐6, R&D Systems, Minneapolis, USA) for 48 h (C). An anti‐human IL‐6 polyclonal antibody (R&D Systems, Minneapolis, USA) was used to neutralize the biological activities of IL‐6 (E, F). To inhibit signal transduction, CAL27cis & Detroit‐562cis cells were pre‐incubated for 1 h with STAT3 inhibitor V (Sigma‐Aldrich, Germany, 500 nmol/L), & then incubated with recombinant human IL‐6 (10 ng/mL) for 24 h before analysis. Data are shown as mean ± SD of 3 independent triplicate cultures (A, B, D, E, F, H). *P < .05, **P < .01 & ***P < .001, compared with the results of control without IL‐6 (D), control IgG (E, F) & with IL‐6 alone (H) Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29761938), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202416175266.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - ZNF24 promoted PD-L1 expression through binding to its promoter in FFA-treated LO2 cells. (a) A schematic of the target sites (wild & mutant) of ZNF24 in the promoter of PD-L1. (b–d) Dual-luciferase reporter assays performed in LO2 cells transfected with WT or MT plasmid containing ZNF24-binding sites in the PD-L1 promoter using Lipofectamine 2000 after ZNF24 overexpression. (e–g) ZNF24 expression after FFA treatment determined by qRT-PCR & western blot. (h & i) ZNF24 expression in LO2 cells pretreated with siRNA against NOX4, MitoTEMPO (10 μM), or NAC (5 mM) followed by FFA treatment, measured by western blot. (j & k) ZNF24 & PD-L1 expression in LO2 cells pretreated with siRNA against ZNF24, followed by FFA treatment detected by western blot. ∗∗P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35615575), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202416165623.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - LfcinB reduced IL‐6‐dependent PD‐L1 expression in cisplatin‐resistant HNSCC cells (A‐C) & inhibited the xenograft growth from CAL27cis & Detroit‐562cis (D, E). The markedly decreased IL‐6 (A) by ELISA & PD‐L1 by WB (B, C) in the acquired cisplatin‐resistant cells were detected. In figure A, C & D, data are shown as mean ± SD of 3 independent triplicate cultures. *P < .05 & **P < .01, compared with the results of control without IL‐6 (A, C). To investigate the effects of LfcinB on in vivo growth of CAL27cis & Detroit‐562cis, we treated nude mice carrying CAL27cis (D) & Detroit‐562cis (E) xenografts with once‐daily injection of 0.75 mg LfcinB (n = 5). Tumor growth of HNSCC xenografts displayed significant reduction after 3 days of LfcinB treatment, compared to control with saline (*P < .05 for LfcinB) Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29761938), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202416175227.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - Identification of ZNF24–UBE2I protein interactions. (a & b) Analysis of protein interactions between ZNF24 & UBE2I using the BioGRID database, further confirmed by Co-IP assays. (c–f) UBE2I expression in LO2 cells treated by FFA or pretreated with siRNA against NOX4, MitoTEMPO (10 μM), or NAC (5 mM) followed by FFA treatment measured by western blot. (g & h) After FFA treatment, Sumo-1: ZNF24 & ZNF24 expression levels detected by western blot. (i & j) After UBE2I overexpression, Sumo-1: ZNF24, ZNF24, PD-L1, & UBE2I expression levels were determined by western blot. (k–m) Dual-luciferase reporter assays performed in LO2 cells transfected with WT plasmid containing ZNF24-binding sites in the PD-L1 promoter using Lipofectamine 2000 after ZNF24 overexpression with or without Sumo-1 overexpression. ∗∗P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35615575), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202416175269.jpg)
![Western Blot: Rad50 Antibody (13B3) [NB100-147] - HeLa whole cell and nuclear extracts (30 ug) were separated by 5% SDS-PAGE, and the membrane was blotted with Rad50 antibody [N1N2], N-term diluted at 1:500.](http://images.novusbio.com/fullsize/Rad50-Antibody-13B3-Western-Blot-NB100-147-img0011.jpg "Western Blot: Rad50 Antibody (13B3) [NB100-147] - HeLa whole cell and nuclear extracts (30 ug) were separated by 5% SDS-PAGE, and the membrane was blotted with Rad50 antibody [N1N2], N-term diluted at 1:500.")
![Immunocytochemistry/Immunofluorescence: Rad50 Antibody (13B3) [NB100-147] - HeLa cells were fixed in 4% paraformaldehyde at RT for 15 min. Green: Rad50 protein stained by Rad50 antibody [13B3] diluted at 1:200. Red: phalloidin, a cytoskeleton marker, diluted at 1:200. Scale bar = 10um.](http://images.novusbio.com/fullsize/Rad50-Antibody-13B3-Immunocytochemistry-Immunofluorescence-NB100-147-img0008.jpg)
![Immunohistochemistry-Paraffin: Rad50 Antibody (13B3) [NB100-147] - Human lung cancer. Rad50 stained by Rad50 antibody [13B3] diluted at 1:100.Antigen Retrieval: Citrate buffer, pH 6.0, 15 min](http://images.novusbio.com/fullsize/Rad50-Antibody-13B3-Immunohistochemistry-Paraffin-NB100-147-img0015.jpg)
![Western Blot: Rad50 Antibody (13B3) [NB100-147] - Analysis of RAD50 in 293T cell lysate using anti-RAD50 antibody.Image submitted by a verified customer review.](http://images.novusbio.com/fullsize/Rad50-Antibody-13B3-Western-Blot-NB100-147-img0007.jpg)
![Immunohistochemistry-Paraffin: Rad50 Antibody (13B3) [NB100-147] - CAL 27 xenograft. Rad50 antibody [13B3] diluted at 1:200. Antigen Retrieval: Citrate buffer, pH 6.0, 15 min](http://images.novusbio.com/fullsize/Rad50-Antibody-13B3-Immunohistochemistry-Paraffin-NB100-147-img0009.jpg)
![Immunohistochemistry-Paraffin: Rad50 Antibody (13B3) [NB100-147] - PC-3 xenograft. Rad50 antibody [13B3] diluted at 1:200. Antigen Retrieval: Citrate buffer, pH 6.0, 15 min](http://images.novusbio.com/fullsize/Rad50-Antibody-13B3-Immunohistochemistry-Paraffin-NB100-147-img0010.jpg)
![Immunohistochemistry-Paraffin: Rad50 Antibody (13B3) [NB100-147] - Human lung cancer. Rad50 stained by Rad50 antibody [13B3] diluted at 1:100.Antigen Retrieval: Citrate buffer, pH 6.0, 15 min](http://images.novusbio.com/fullsize/Rad50-Antibody-13B3-Immunohistochemistry-Paraffin-NB100-147-img0014.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: Rad50 Antibody (13B3) [NB100-147] - Non-transfected (-) and transfected (+) HeLa whole cell extracts (30 ug) were separated by 5% SDS-PAGE, and the membrane was blotted with Rad50 antibody [13B3].](http://images.novusbio.com/fullsize/Rad50-Antibody-13B3-Western-Blot-NB100-147-img0013.jpg)
![Western Blot: Rad50 Antibody (13B3) [NB100-147] - Various whole cell extracts (30 ug) were separated by 5% SDS-PAGE, and the membrane was blotted with Rad50 antibody [13B3] (NB100-147) diluted at 1:1000. The HRP-conjugated anti-mouse IgG antibody was used to detect the primary antibody.](http://images.novusbio.com/fullsize/nb100-147_mouse-monoclonal-rad50-antibody-13b3-91020242091495.jpg)
![Immunohistochemistry: EGLN1/PHD2 Antibody [NB100-2219] - IHC and Immunofluorescence of wounded tissue and normal unwounded skin. Representative images for immunofluorescent staining of PHD-2 on healed wounded skin and adjacent normal unwounded skin of wild type, heterozygous K14-Cre/homozygous floxed PHD-2, and heterozygous Col1 alpha2-Cre-ER/homozygous floxed PHD-2 mice at 400x magnification. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0093373), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/EGLN1-PHD2-Antibody-Immunohistochemistry-NB100-2219-img0015.jpg "Immunohistochemistry: EGLN1/PHD2 Antibody [NB100-2219] - IHC and Immunofluorescence of wounded tissue and normal unwounded skin. Representative images for immunofluorescent staining of PHD-2 on healed wounded skin and adjacent normal unwounded skin of wild type, heterozygous K14-Cre/homozygous floxed PHD-2, and heterozygous Col1 alpha2-Cre-ER/homozygous floxed PHD-2 mice at 400x magnification. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0093373), licensed under a CC-BY license.")
![<b>Genetic Strategies Validation. </b>Western Blot: EGLN1/PHD2 Antibody [NB100-2219] - In vitro analysis of PHD-2 knockout and protein quantification.Western blot data for PHD-2 knockout in fibroblasts of heterozygous Col1 alpha2-Cre-ER/homozygous floxed PHD-2 mice compared to wild type mice (*p<0.05). D') Western blot data for PHD-2 knockout in keratinocytes of heterozygous K14-Cre/homozygous floxed PHD-2 mice compared to wild type mice (*p<0.05). Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0093373), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/EGLN1-PHD2-Antibody-Knockdown-Validated-NB100-2219-img0016.jpg)
![Immunohistochemistry-Paraffin: EGLN1/PHD2 Antibody [NB100-2219] - Analysis of an FFPE mouse lung section using 1:200 dilution of EGLN1/PHD2 antibody. The staining was developed using HRP conjugated anti-rabbit secondary antibody and DAB reagent. The antibody generated a specific staining in the cytoplasm and nuclei of alveolar as well as bronchiolar epithelial cells. Cytoplasmic staining was observed in almost all cells while the nuclear positivity was seen in a subset of cells only.](http://images.novusbio.com/fullsize/EGLN1-PHD2-Antibody-Immunohistochemistry-Paraffin-NB100-2219-img0014.jpg)
![Western Blot: EGLN1/PHD2 Antibody [NB100-2219] - Detection of EGLN1/PHD2 in mouse kidney lysate. ECL exposure, 20 seconds.](http://images.novusbio.com/fullsize/EGLN1-PHD2-Antibody-Western-Blot-NB100-2219-img0013.jpg)
![Immunocytochemistry/Immunofluorescence: EGLN1/PHD2 Antibody [NB100-2219] - EGLN1/PHD2 antibody at 1:500 in HeLa cells with DyLight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and DyLight 550 (red).](http://images.novusbio.com/fullsize/EGLN1-PHD2-Antibody-Immunocytochemistry-Immunofluorescence-NB100-2219-img0012.jpg)
![Immunocytochemistry/Immunofluorescence: EGLN1/PHD2 Antibody [NB100-2219] - Analysis of EGLN1/PHD2 in ARPE-19 cells using anti-PHD2 antibody. ICC/IF image submitted by a veriifed customer review.](http://images.novusbio.com/fullsize/EGLN1-PHD2-Antibody-Immunocytochemistry-Immunofluorescence-NB100-2219-img0009.jpg)
![Immunohistochemistry: EGLN1/PHD2 Antibody [NB100-2219] - Staining of renal tubular epithelium in mouse using NB100-2219 at 2.5 ug/mL.](http://images.novusbio.com/fullsize/EGLN1-PHD2-Antibody-Immunohistochemistry-NB100-2219-img0010.jpg)
![Hydralazine enhances NRF2 signaling in SH-SY5Y cells. c Hydralazine reduced the interaction between NRF2 and KEAP1. Interactions were measured by reciprocal Co-IPs followed by western blot analysis. *p 0.05). n = 5–6/group. * P Sample: Neuro2A cells were fixed in 4% paraformaldehyde at RT for 15 min.Green: Nrf2 stained by Nrf2 antibody [N2C2], Internal (NBP1-32822) diluted at 1:1000.](http://images.novusbio.com/fullsize/nbp1-32822_rabbit-polyclonal-nrf2-antibody-91020242021994.jpg "Hydralazine enhances NRF2 signaling in SH-SY5Y cells. c Hydralazine reduced the interaction between NRF2 and KEAP1. Interactions were measured by reciprocal Co-IPs followed by western blot analysis. *p 0.05). n = 5–6/group. * P Sample: Neuro2A cells were fixed in 4% paraformaldehyde at RT for 15 min.Green: Nrf2 stained by Nrf2 antibody [N2C2], Internal (NBP1-32822) diluted at 1:1000.")
![Immunohistochemistry-Paraffin: Nrf2 Antibody [NBP1-32822] - Nrf2 antibody [N2C2], Internal detects Nrf2 protein at cytoplasm and nucleus by immunohistochemical analysis.Sample: Paraffin-embedded human breast carcinoma.Nrf2 stained by Nrf2 antibody [N2C2], Internal (NBP1-32822) diluted at 1:500.Antigen Retrieval: Citrate buffer, pH 6.0, 15 min](http://images.novusbio.com/fullsize/nbp1-32822_rabbit-polyclonal-nrf2-antibody-910202420115018.jpg)
![Western Blot: Nrf2 Antibody [NBP1-32822] - Untreated (-) and treated (+) Rat2 whole cell extracts (30 ug) were separated by 5% SDS-PAGE, and the membrane was blotted with Nrf2 antibody [N2C2], Internal (NBP1-32822) diluted at 1:2000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody, and the signal was developed with Trident ECL plus-Enhanced.](http://images.novusbio.com/fullsize/nbp1-32822_rabbit-polyclonal-nrf2-antibody-910202419593583.jpg)
![Western Blot: Nrf2 Antibody [NBP1-32822] - Untreated (-) and treated (+) HepG2 whole cell extracts (30 ug) were separated by 5% SDS-PAGE, and the membrane was blotted with Nrf2 antibody [N2C2], Internal (NBP1-32822) diluted at 1:2000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.](http://images.novusbio.com/fullsize/nbp1-32822_rabbit-polyclonal-nrf2-antibody-91020242063329.jpg)
![Immunocytochemistry/ Immunofluorescence: Nrf2 Antibody [NBP1-32822] - Nrf2 antibody [N2C2], Internal detects Nrf2 protein at nucleus by immunofluorescent analysis.Sample: HeLa cells were fixed in 4% paraformaldehyde at RT for 15 min.Green: Nrf2 stained by Nrf2 antibody [N2C2], Internal (NBP1-32822) diluted at 1:1000.Red: phalloidin, a cytoskeleton marker, diluted at 1:200.Scale bar= 10 um.](http://images.novusbio.com/fullsize/nbp1-32822_rabbit-polyclonal-nrf2-antibody-9102024202465.jpg)
